> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Novo Nordisk NDA for Diabetes
- URL: https://www.fdaweb.com/panel-to-discuss-novo-nordisk-nda-for-diabetes/
- Published: 2016-03-17T12:00:00.000Z
- Updated: 2026-09-15T02:44:47.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135120

*Federal Register* Notice: FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will meet 5/25 from 8 a.m. to 5 p.m. at FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503), 10903 New Hampshire Ave., Silver Spring, MD. The committee will discuss the safety and efficacy of a Novo Nordisk NDA for insulin degludec and liraglutide injection for the proposed indication: Adjunct to diet and exercise to improve glycemic control in the treatment of adults with Type 2 diabetes mellitus. Contact **LaToya Bonner**, (301) 796-9001\. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-03-17/pdf/2016-05959.pdf?ref=fdaweb.com)